Introduction
The pharmaceutical industry is ever changing and always growing, no matter what country you may live in pharmaceuticals are necessary. This industry is associated with major modifications and innovations which require extensive research to be conducted on an ongoing basis. In order to remain competitive and viable pharmaceutical companies have allocated resources to research and development.
Eli Lilly is a pharmaceutical company that was founded by Colonel Eli Lilly, who was a pharmacist who had served in the Union Army during the Civil war. In 1876 Eli Lilly purchased a small laboratory on Pearl Street in Indianapolis, Indiana. The Eli Lilly Company has seen a lot of success over the years through their production of various
…show more content…
*Asset 2: OFC (olanzapine-fluoxetine combination)- OFC combined the active ingredient in Zypreza and the active ingredient in Prozac.
*Asset 3: 5HT2 antagonist SSRI- different specificities in the receptor sites for serotonin, resulting in diverse side effect profiles and efficacy for targeted symptoms.
* Asset 4: Business development Opportunities- through market surveillance and due diligence, Lilly identified 13 opportunities to in-license compounds for the treatment of depression from other pharmaceutical companies at various stages in their development.
*Asset 5: Cymbalta (duloxetine)- Cymbalta was a serotonin and norepinephrine receptor inhibitor (SNRI) that was developed by Lilly in the early 1990s for the MMD(Major Depressive Disorder) market.
* (Ofek & Laufer, 2008, p.
…show more content…
With this discovery The Eli Lilly Company can now use Cymbalta to treat chronic pain and depression in patients. However, the main strategic issues and problems that Eli Lilly and Company faced with this discovery is that: option 1 “conduct a new set of clinical trials to establish a one-a-day dosage of 60mg for Cymbalta to treat major depressive disorder… option two invest in the clinical trials for a new indication that could potentially establish a point of differentiation between Cymbalta and existing antidepressants … option three is to delay the submission of Cymbalta to the FDA for marketing approval” (Ofek & Laufer, 2008, p. 2). In developing a new drug like Cymbalta the NAT would have to focus in on their clinical trials and allow for proper research and development to minimize on the severity of side effects. However in order complete clinical trials on a large scale budget $25-$50 million dollars has to be allocated towards this process. “This includes design, enroll patients, analyze and document the findings of the clinical trial” (Ofek & Laufer, 2008, p.